Skip to content

OSA in Never Smokers With Lung Cancer

Obstructive Sleep Apnea in Never Smokers With Newly Diagnosed Lung Cancer: Prevalence and Impact on Prognosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05224180
Enrollment
77
Registered
2022-02-04
Start date
2021-11-03
Completion date
2024-06-24
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Obstructive Sleep Apnea

Brief summary

Previous studies have yielded inconsistent findings regarding the association between obstructive sleep apnea and the prevalence and mortality of lung cancer. Smoking history, a common risk factor for lung cancer, chronic obstructive pulmonary disease, and obstructive sleep apnea, may act as a confounding variable, limiting interpretation of the results. The aim of this study is to evaluate the prevalence of obstructive sleep apnea in never smokers with lung cancer and to determine the effect of obstructive sleep apnea on the prognosis of lung cancer. Enrolled patients will undergo respiratory polygraphy before beginning treatment for lung cancer. This prospective cohort includes both cross sectional and longitudinal analyses.

Interventions

None listed

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

\- Never smokers who are admitted to the Seoul National University Hospital and newly diagnosed with lung cancer, with ECOG Performance Status 0 or 1

Exclusion criteria

* Patients who have received treatment for lung cancer before the enrollment * Patients who have received treatment for OSA before the enrollment * Patients with an expected life expectancy of less than 3 months * Patients with neuromuscular disease, chronic opioid medication use, or severe insomnia not controlled by medication * Patients receiving supplemental oxygen therapy due to underlying diseases including heart failure, chronic obstructive pulmonary disease, interstitial pulmonary disease, hypoventilation syndrome, stroke, or whose baseline oxygen saturation is less than 90% * Patients with unstable medical conditions within the preceding 3 months (hospitalization due to acute exacerbation of underlying lung disease, diagnosis of unstable angina or myocardial infarction, history of percutaneous coronary intervention or coronary artery bypass surgery, or diagnosis of transient ischemic attack or stroke) * Patients with an inability or unwillingness to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of obstructive sleep apnea in never smokers with lung cancer1 weekA primary outcome measure in a cross-sectional analysis of a prospective cohort study
Effects of obstructive sleep apnea on lung cancer mortality and overall mortalityFollow up for 5 yearsA primary outcome measure in a longitudinal analysis of prospective cohort study

Secondary

MeasureTime frameDescription
Association between apnea-hyponea index (AHI) and the stage of lung cancer1 weekA secondary outcome measure in a cross-sectional analysis of a prospective cohort study.
Association between the oxygen desaturation index (ODI) and the stage of lung cancer1 weekA secondary outcome measure in a cross-sectional analysis of a prospective cohort study.
Association between the sleep time spent with oxygen saturation< 90% (TS90) and the stage of lung cancer1 weekA secondary outcome measure in a cross-sectional analysis of a prospective cohort study.
Effect of the apnea-hyponea index (AHI) on lung cancer mortality and overall mortalityFollow up for 5 yearsA secondary outcome measure in a longitudinal analysis of prospective cohort study.
Effect of the oxygen desaturation index (ODI) on lung cancer mortality and overall mortalityFollow up for 5 yearsA secondary outcome measure in a longitudinal analysis of prospective cohort study.
Effect of the sleep time spent with oxygen saturation< 90% (TS90) on lung cancer mortality and overall mortalityFollow up for 5 yearsA secondary outcome measure in a longitudinal analysis of prospective cohort study.

Countries

South Korea

Contacts

PRINCIPAL_INVESTIGATORJaeyoung Cho, M.D., Ph.D.

Seoul National University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026